Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$749.92
Market cap
$711.91B
P/E Ratio
80.72
Dividend/share
$5.2
EPS
$9.29
Enterprise value
$739.66B
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded
Highlights
The net income has soared by 68% YoY and by 14% from the previous quarter
The EPS has soared by 68% YoY and by 14% QoQ
The P/E is 48% above the 5-year quarterly average of 54.4 but 23% below the last 4 quarters average of 105.2
ELI LILLY's debt has soared by 54% YoY and by 8% from the previous quarter
Key stats
What are the main financial stats of LLY
Market
Valuations
Earnings
Shares outstanding
949.32M
Market cap
$711.91B
Enterprise value
$739.66B
Price to earnings (P/E)
80.72
Price to book (P/B)
50.05
Price to sales (P/S)
16.54
EV/EBIT
72.87
EV/EBITDA
62.58
EV/Sales
18.1
Revenue
$40.86B
EBIT
$10.15B
EBITDA
$11.82B
Free cash flow
$1.4B
Per share
Balance sheet
Liquidity
EPS
$9.29
Free cash flow per share
$1.55
Book value per share
$14.98
Revenue per share
$45.35
TBVPS
$70.26
Total assets
$75.61B
Total liabilities
$61.29B
Debt
$31.12B
Equity
$14.24B
Working capital
$6.74B
Debt to equity
2.19
Current ratio
1.27
Quick ratio
0.63
Net debt/EBITDA
2.35
Margins
Efficiency
Dividend
EBITDA margin
28.9%
Gross margin
80.9%
Net margin
20.5%
Operating margin
24.8%
Return on assets
12.2%
Return on equity
65.2%
Return on invested capital
17.7%
Return on capital employed
19.9%
Return on sales
24.8%
Dividend yield
0.69%
DPS
$5.2
Payout ratio
56%
LLY stock price
How has the ELI LILLY stock price performed over time
Intraday
-0.46%
1 week
-4.62%
1 month
-17.24%
1 year
26.55%
YTD
28.65%
QTD
-15.35%
Financial performance
How have ELI LILLY's revenue and profit performed over time
Revenue
$40.86B
Gross profit
$33.06B
Operating income
$10.15B
Net income
$8.37B
Gross margin
80.9%
Net margin
20.5%
The net income has soared by 68% YoY and by 14% from the previous quarter
LLY's operating income has surged by 65% year-on-year and by 13% since the previous quarter
The company's gross profit rose by 31% YoY and by 5% QoQ
ELI LILLY's net margin has increased by 31% YoY and by 8% from the previous quarter
Growth
What is ELI LILLY's growth rate over time
Valuation
What is ELI LILLY stock price valuation
P/E
80.72
P/B
50.05
P/S
16.54
EV/EBIT
72.87
EV/EBITDA
62.58
EV/Sales
18.1
The EPS has soared by 68% YoY and by 14% QoQ
The P/E is 48% above the 5-year quarterly average of 54.4 but 23% below the last 4 quarters average of 105.2
LLY's P/B is 28% above its 5-year quarterly average of 39.0 but 14% below its last 4 quarters average of 57.9
The equity has increased by 27% year-on-year and by 5% since the previous quarter
The stock's price to sales (P/S) is 53% more than its 5-year quarterly average of 10.8 but 12% less than its last 4 quarters average of 18.8
ELI LILLY's revenue has increased by 27% YoY and by 5% from the previous quarter
Efficiency
How efficient is ELI LILLY business performance
The company's return on equity rose by 44% YoY and by 7% QoQ
The ROA has grown by 31% YoY and by 7% from the previous quarter
The ROS has increased by 29% YoY and by 7% QoQ
The ROIC has grown by 16% YoY
Dividends
What is LLY's dividend history
DPS
$5.2
Dividend yield
0.69%
Payout ratio
56%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did ELI LILLY financials performed over time
LLY's total assets is 23% greater than its total liabilities
LLY's total assets is up by 31% year-on-year and by 5% since the previous quarter
ELI LILLY's total liabilities has increased by 31% YoY and by 5% from the previous quarter
ELI LILLY's debt is 119% more than its equity
ELI LILLY's debt has soared by 54% YoY and by 8% from the previous quarter
The equity has increased by 27% year-on-year and by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.